89Zr-Patritumab deruxtecan
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Carcinoma
Conditions
Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation
Trial Timeline
Mar 3, 2025 → May 1, 2028
NCT ID
NCT06222489About 89Zr-Patritumab deruxtecan
89Zr-Patritumab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Non-Small Cell Lung Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06222489. Target conditions include Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Carcinoma were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06222489 | Phase 2 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Carcinoma